Table.
Baseline characteristics of the intention-to-treat population
|
Cohort 1A |
Cohort 1B |
Cohort 2 |
|||
|---|---|---|---|---|---|
| DSM265 (n=6) | Placebo (n=2) | Atovaquone-proguanil (n=6) | DSM265 (n=6) | Placebo (n=2) | |
| Age (years) | 25·0 (22·0–28·0) | 27·0 (25·0–29·0) | 25·5 (23·5–29·8) | 25·5 (22·3–28·8) | 25·0 (23·5–26·5) |
| Sex (male) | 4 (66%) | 1 (50%) | 4 (66%) | 4 (66%) | 1 (50%) |
| Weight (kg) | 67·5 (58·3–79·0) | 70·0 (59·5–80·5) | 76·0 (64·8–91·0) | 87·0 (72·8–88·5) | 64·0 (63·5–64·5) |
| Height (cm) | 178·0 (167·5–179·5) | 165·0 (160·0–170·0) | 181·0 (168·8–182·0) | 181·5 (177·8–185·2) | 167·5 (163·8–171·2) |
| Body-mass index (kg/m2) | 22·3 (20·4–23·9) | 25·0 (22·7–27·4) | 24·5 (22·4–27·9) | 25·7 (24·0–26·7) | 22·9 (22·0–23·8) |
Data are n (%) and median (IQR).